Eqis Capital Management Inc. Purchases Shares of 2,606 Clorox Co (NYSE:CLX)

Eqis Capital Management Inc. purchased a new stake in shares of Clorox Co (NYSE:CLX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,606 shares of the company’s stock, valued at approximately $396,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Tower View Investment Management & Research LLC raised its position in Clorox by 19.4% during the second quarter. Tower View Investment Management & Research LLC now owns 387 shares of the company’s stock valued at $59,000 after purchasing an additional 63 shares in the last quarter. World Asset Management Inc increased its holdings in shares of Clorox by 0.7% in the second quarter. World Asset Management Inc now owns 9,872 shares of the company’s stock worth $1,512,000 after buying an additional 65 shares during the period. Nvwm LLC increased its holdings in shares of Clorox by 1.7% in the third quarter. Nvwm LLC now owns 4,248 shares of the company’s stock worth $645,000 after buying an additional 71 shares during the period. Arrow Financial Corp increased its holdings in shares of Clorox by 9.2% in the second quarter. Arrow Financial Corp now owns 892 shares of the company’s stock worth $137,000 after buying an additional 75 shares during the period. Finally, Cypress Capital Group increased its holdings in shares of Clorox by 1.8% in the second quarter. Cypress Capital Group now owns 4,312 shares of the company’s stock worth $660,000 after buying an additional 75 shares during the period. Institutional investors and hedge funds own 78.56% of the company’s stock.

NYSE CLX opened at $145.30 on Friday. The company has a debt-to-equity ratio of 4.69, a current ratio of 0.87 and a quick ratio of 0.52. The stock has a market capitalization of $18.49 billion, a PE ratio of 22.99, a PEG ratio of 4.71 and a beta of 0.38. Clorox Co has a 1 year low of $143.58 and a 1 year high of $167.70. The business’s 50-day moving average is $149.38 and its 200 day moving average is $154.09.

Clorox (NYSE:CLX) last posted its earnings results on Thursday, October 31st. The company reported $1.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.54 by $0.05. Clorox had a return on equity of 123.56% and a net margin of 13.20%. The company had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.51 billion. During the same period last year, the firm earned $1.62 earnings per share. Clorox’s quarterly revenue was down 3.6% on a year-over-year basis. As a group, equities research analysts anticipate that Clorox Co will post 6.16 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 15th. Shareholders of record on Wednesday, October 30th were issued a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a dividend yield of 2.92%. The ex-dividend date was Tuesday, October 29th. Clorox’s dividend payout ratio (DPR) is presently 67.09%.

Several research analysts have recently commented on the company. Cfra downgraded Clorox from a “hold” rating to a “sell” rating in a report on Friday, November 1st. Barclays set a $138.00 price objective on Clorox and gave the stock a “sell” rating in a report on Friday, November 1st. Bank of America decreased their price objective on Clorox from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, October 3rd. Credit Suisse Group decreased their price objective on Clorox from $172.00 to $168.00 and set an “outperform” rating on the stock in a report on Thursday, October 3rd. Finally, Wells Fargo & Co reiterated a “hold” rating and issued a $150.00 price objective on shares of Clorox in a report on Wednesday, October 2nd. Five equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the stock. Clorox presently has an average rating of “Hold” and an average price target of $152.00.

In other news, SVP Michael R. Costello sold 6,997 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $162.56, for a total transaction of $1,137,432.32. Following the sale, the senior vice president now directly owns 29,016 shares in the company, valued at approximately $4,716,840.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael R. Costello sold 3,225 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $161.34, for a total transaction of $520,321.50. Following the sale, the senior vice president now owns 29,669 shares in the company, valued at $4,786,796.46. The disclosure for this sale can be found here. Insiders have sold a total of 15,870 shares of company stock valued at $2,484,000 in the last three months. Insiders own 1.14% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Further Reading: Day Trading – Risk Worth the Reward?

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.